<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00789373</url>
  </required_header>
  <id_info>
    <org_study_id>12560</org_study_id>
    <secondary_id>H3E-EW-S124</secondary_id>
    <secondary_id>CTRI/2009/091/000113</secondary_id>
    <nct_id>NCT00789373</nct_id>
  </id_info>
  <brief_title>A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Immediately Following Induction Treatment With Pemetrexed + Cisplatin for Advanced Non-squamous Non-Small Cell Lung Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare progression-free survival in patients with advanced non-squamous
      non-small cell lung cancer. Patients who do not progress following 4 cycles of induction
      treatment with pemetrexed and cisplatin will be randomized 2:1 to receive either maintenance
      pemetrexed or placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator-assessed Objective Progression-free Survival (PFS)</measure>
    <time_frame>Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)</time_frame>
    <description>Investigator-assessed objective PFS was measured from the date of randomization to the first date of objectively determined progressive disease (PD) or death from any cause. For patients not known to have died as of the data cutoff date and who did not have objective PD, PFS was censored at the date of last objective tumor assessment. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD = 20% increase in sum of longest diameter of target lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Independently-assessed Objective Progression-free Survival (PFS)</measure>
    <time_frame>Date of randomization to first date of measured PD or date of death from any cause (up to 19.3 months)</time_frame>
    <description>To further evaluate the robustness of the PFS analysis, Lilly established an independent review of PFS to assess the potential for investigator bias in the determination of objective PD. PFS was measured from the date of randomization to the first date of objectively determined PD or death. For patients alive as of the data cutoff date and who did not have PD, PFS was censored at the date of the last objective tumor assessment. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD = 20% increase in sum of longest diameter of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Date of randomization to the date of death from any cause up to 39.5 months</time_frame>
    <description>OS is the duration from enrollment to death. For patients who are alive, OS is censored at the last contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the EuroQol Instrument (EQ-5D) Index Score</measure>
    <time_frame>Baseline randomization through 30-day post-discontinuation visit (up to 19.3 months)</time_frame>
    <description>The EQ-5D is a generic instrument that describes health status in 5 attributes (mobility, self-care, pain/discomfort, anxiety/depression, usual activities) using a three level scale (no problem, some problems, and major problems). These combinations of attributes are converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score range from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EuroQol Instrument (EQ-5D) Visual Analog Scale (VAS)</measure>
    <time_frame>Baseline randomization through 30-day post-discontinuation visit (up to 19.3 months)</time_frame>
    <description>Patients indicate their present health state through completion of the VAS. Possible scores range from 0 (worst imaginable health state) to 100 (best imaginable health state).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Hospitalizations Due to Adverse Events or Requiring Transfusion (Resource Utilization)</measure>
    <time_frame>Baseline randomization through 30-day post-discontinuation visit (up to 19.3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Non-Serious Adverse Event (AE) During Maintenance Phase</measure>
    <time_frame>Baseline randomization through 30-day post-discontinuation visit (up to 49.7 months)</time_frame>
    <description>A summary of non-serious AEs is located in the Reported Adverse Event Module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serious Adverse Events During Maintenance Phase</measure>
    <time_frame>Baseline randomization through 30-day post-discontinuation visit (up to 49.7 months)</time_frame>
    <description>A summary of serious adverse events is located in the Reported Adverse Event Module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Objective Tumor Response (Response Rate) During Maintenance Phase of Study up to Primary Data Cut-Off</measure>
    <time_frame>Baseline to date of measured progressive disease (up to 19.3 months)</time_frame>
    <description>Analysis for combined phases was not performed since response was calculated separately for each phase of study. Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response(PR)is at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease(PD) is at least a 20% increase in sum of longest diameter of target lesions; Stable Disease(SD)=no change or small changes that do not meet the above criteria for CR, PR, or PD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Independently-Assessed Objective Tumor Response (Response Rate) During Maintenance Phase Up to Primary Data Cut-Off</measure>
    <time_frame>Date of randomization to date of measured PD (up to 19.3 months)</time_frame>
    <description>Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response (PR) is at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) is at least a 20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=no change or small changes that do not meet the above criteria for CR, PR, or PD. Response Rate = (CR+PR)/Participants in Arm*100. Disease Control Rate=(CR+PR+SD)/Number of Participants in Arm*100.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">939</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>pemetrexed + cisplatin followed by pemetrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pemetrexed plus cisplatin followed by pemetrexed plus best supportive care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pemetrexed + cisplatin followed by placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>pemetrexed plus cisplatin followed by placebo plus best supportive care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Induction therapy: 500 mg/m^2, intravenous (IV), on Day 1 of each 21-day cycle for 4 cycles</description>
    <arm_group_label>pemetrexed + cisplatin followed by pemetrexed</arm_group_label>
    <arm_group_label>pemetrexed + cisplatin followed by placebo</arm_group_label>
    <other_name>Alimta</other_name>
    <other_name>LY231514</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Induction therapy: Cisplatin: 75 mg/m^2, IV, on Day 1 of each 21-day cycle for 4 cycles</description>
    <arm_group_label>pemetrexed + cisplatin followed by pemetrexed</arm_group_label>
    <arm_group_label>pemetrexed + cisplatin followed by placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Maintenance therapy: Normal saline (0.9% sodium chloride) administered IV on Day 1 every 21-day cycle until progressive disease or treatment discontinuation</description>
    <arm_group_label>pemetrexed + cisplatin followed by placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Maintenance therapy: 500 mg/m^2, IV, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation.</description>
    <arm_group_label>pemetrexed + cisplatin followed by pemetrexed</arm_group_label>
    <other_name>Alimta</other_name>
    <other_name>LY231514</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Supportive Care</intervention_name>
    <description>Best Supportive Care is treatment given with the intent to maximize quality of life. Best Supportive Care excludes any treatment in which the goal is to cure or slow the progression of the study disease. Patients will receive Best Supportive Care as judged by their treating physician. Those therapies considered acceptable include, but are not limited to, palliative radiation to extrathoracic structures, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral).</description>
    <arm_group_label>pemetrexed + cisplatin followed by pemetrexed</arm_group_label>
    <arm_group_label>pemetrexed + cisplatin followed by placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for the Induction Phase:

          -  You must sign an informed consent document for clinical research.

          -  You must have Stage IIIB or IV nonsquamous Non-Small Cell Lung Cancer.

          -  You must at least be able to be physically mobile, take care of yourself, and must be
             up and about and able to perform light activities such as light housework or office
             work.

          -  You are allowed to have had prior radiation therapy as long as it was not to more than
             25% of the bone marrow and did not include the whole pelvis. Thoracic radiation must
             be completed more than 30 days before the study. You must be recovered from the toxic
             effects (except hair loss).

          -  You must have at least 1 measurable tumor lesion according to the Response Evaluation
             Criteria in Solid Tumors (RECIST) guidelines or disease that can be evaluated by
             computed tomography (CT) Scan.

          -  Your test results assessing the function of your blood forming tissue, kidneys, and
             liver must be satisfactory.

          -  You must be 18 years of age or older.

          -  Women must be sterile, postmenopausal or on contraception and men must be on
             contraception or sterile (e.g. post-vasectomy).

        Exclusion Criteria for the Induction Phase:

          -  You cannot have squamous cell and/or mixed small cell, non-small cell lung cancer

          -  You cannot have received other investigational drugs within the last 30 days of
             entering the trial.

          -  You cannot have previously completed or withdrawn from this study or any other study
             investigating pemetrexed.

          -  You cannot have other serious on-going illnesses including active infections.

          -  You cannot have a serious cardiac condition, such as a heart attack, angina, or heart
             disease within 6 months of entering the trial.

          -  You cannot have had another form of cancer other than superficial basal cell and
             superficial squamous (skin) cell cancer, or carcinoma in situ of the cervix within the
             last 5 years. Patients with a history of low-grade (Gleason score less than or equal
             to 6) localized prostate cancer will be eligible even if diagnosed less than 5 years
             ago.

          -  You cannot have known central nervous system (CNS) metastases, other than treated,
             stable brain metastasis.

          -  You cannot be receiving nor have received any prior systemic anticancer therapy for
             lung cancer (including chemotherapy given after surgery in early-stage treatment).

          -  You cannot have clinically significant third-space fluid collections (e.g. ascites or
             pleural effusions that cannot be controlled by drainage or other procedures).

          -  You cannot have received a recent (within 30 days) or are receiving a yellow fever
             vaccination.

          -  You are unable to stop taking more than 1.3 grams of aspirin on a daily basis or other
             non-steroidal anti-inflammatory drugs (NSAIDs).

          -  You are unable or unwilling to take folic acid, injections of vitamin B12, or
             corticosteroids.

          -  You cannot be pregnant or breastfeeding.

        Inclusion criteria at Randomization for the Maintenance Phase:

          -  You must at least be able to be physically mobile, take care of yourself, and must be
             up and about and able to perform light activities such as light housework or office
             work.

          -  You must have documented radiographic evidence of a tumor response of complete
             response (CR), partial response (PR), or stable disease (SD) according to the Response
             Evaluation Criteria in Solid Tumors (RECIST) guidelines. Tumor assessment must occur
             between Cycle 4 (Day 1) of induction therapy and the date of randomization. This
             response does not have to be confirmed in order for the patient to be randomized to
             the maintenance phase.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wendouree</city>
        <state>Victoria</state>
        <zip>3355</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gilly</city>
        <zip>6060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sint Niklaas</city>
        <zip>9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Espoo</city>
        <zip>02740</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Avignon</city>
        <zip>84082</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Le Mans Cedex 1</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Montpellier</city>
        <zip>F-34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nantes</city>
        <zip>44202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vandoeuvre-Les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gerlingen</city>
        <zip>70839</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gro√ühansdorf</city>
        <zip>D-22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chania</city>
        <zip>73300</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Neo Faliro</city>
        <zip>18547</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Patras</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bangalore</city>
        <zip>560 078</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bhopal</city>
        <zip>462001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madurai</city>
        <zip>625020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mumbai</city>
        <zip>400 012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Patna</city>
        <zip>800 014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lido Di Camaiore</city>
        <zip>55043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Monza</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pisa</city>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rome</city>
        <zip>00149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ede</city>
        <zip>6716 RP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Harderwijk</city>
        <zip>3844 DG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Heerlen</city>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Poznan</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Warsaw</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Coimbra</city>
        <zip>3040-853</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lisbon</city>
        <zip>1099-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vila Franca De Xira</city>
        <zip>4434-502</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>3400</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oradea</city>
        <zip>3700</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Manresa</city>
        <zip>308243</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bornova</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sihhiye</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zeytinburnu</city>
        <zip>034760</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guildford</city>
        <state>Surrey</state>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Newcastle</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>India</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2008</study_first_submitted>
  <study_first_submitted_qc>November 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2008</study_first_posted>
  <results_first_submitted>June 20, 2011</results_first_submitted>
  <results_first_submitted_qc>June 20, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 18, 2011</results_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Induction Pemetrexed + Cisplatin</title>
          <description>pemetrexed: 500 mg/m^2, intravenous (IV), on Day 1 of each 21-day cycle for 4 cycles.
cisplatin: 75 mg/m^2, IV, on Day 1 of each 21-day cycle for 4 cycles.</description>
        </group>
        <group group_id="P2">
          <title>Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed</title>
          <description>Following Induction, received 500 mg/m^2 maintenance pemetrexed, IV, on Day 1 of each 21-day cycle plus Best Supportive Care until progressive disease (PD) or treatment discontinuation.</description>
        </group>
        <group group_id="P3">
          <title>Pemetrexed + Cisplatin Followed by Placebo</title>
          <description>Following Induction, received placebo (normal saline [0.9% sodium chloride]) administered IV on Day 1 of every 21-day cycle plus Best Supportive Care until PD or treatment discontinuation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Induction</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="939"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="540">1 patient received maintenance therapy post-induction but was never randomized.</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="399"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death Due to study disease</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death due to adverse event</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death due to toxicity</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death due to procedure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator decision</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol entry criteria not met</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="220"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="359"/>
                <participants group_id="P3" count="180"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="359"/>
                <participants group_id="P3" count="180"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death due to study disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death due to adverse event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death due to toxicity</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol entry criteria not met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="253"/>
                <participants group_id="P3" count="152"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participants On-Going at Data Cut-Off</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Induction Pemetrexed + Cisplatin</title>
          <description>pemetrexed plus cisplatin</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="939"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.3" lower_limit="24.4" upper_limit="83.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="362"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="577"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ever Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Investigator-assessed Objective Progression-free Survival (PFS)</title>
        <description>Investigator-assessed objective PFS was measured from the date of randomization to the first date of objectively determined progressive disease (PD) or death from any cause. For patients not known to have died as of the data cutoff date and who did not have objective PD, PFS was censored at the date of last objective tumor assessment. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD = 20% increase in sum of longest diameter of target lesions.</description>
        <time_frame>Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed</title>
            <description>pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care</description>
          </group>
          <group group_id="O2">
            <title>Pemetrexed + Cisplatin Followed by Placebo</title>
            <description>pemetrexed + cisplatin followed by placebo plus best supportive care</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator-assessed Objective Progression-free Survival (PFS)</title>
          <description>Investigator-assessed objective PFS was measured from the date of randomization to the first date of objectively determined progressive disease (PD) or death from any cause. For patients not known to have died as of the data cutoff date and who did not have objective PD, PFS was censored at the date of last objective tumor assessment. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD = 20% increase in sum of longest diameter of target lesions.</description>
          <population>All randomized participants</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.11" lower_limit="3.15" upper_limit="4.57"/>
                    <measurement group_id="O2" value="2.83" lower_limit="2.60" upper_limit="3.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>900 patients were planned to be enrolled in order to randomize 558 pts to maintenance therapy. This trial was powered for the primary endpoint, PFS (90% power, assuming 238 events with 52% censoring and a PFS Hazard Ratio (HR)=0.65, alpha=0.05). This trial was also powered for a secondary endpoint, OS (93% power, assuming 390 events with 30% censoring and an OS HR=0.70). Alpha was controlled for both a preliminary analysis (alpha=0.0001) and final analysis of OS (alpha=0.0499).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00006</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Independently-assessed Objective Progression-free Survival (PFS)</title>
        <description>To further evaluate the robustness of the PFS analysis, Lilly established an independent review of PFS to assess the potential for investigator bias in the determination of objective PD. PFS was measured from the date of randomization to the first date of objectively determined PD or death. For patients alive as of the data cutoff date and who did not have PD, PFS was censored at the date of the last objective tumor assessment. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD = 20% increase in sum of longest diameter of target lesions.</description>
        <time_frame>Date of randomization to first date of measured PD or date of death from any cause (up to 19.3 months)</time_frame>
        <population>Randomized participants with reviewable scan--(316/359 [88%] Maintenance arm and 156/180 [87%] Placebo comparator arm. The majority of unread scans (12.4%) were due to participants not completing 1 cycle of treatment by the data cutoff date (30 June 2010).</population>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed</title>
            <description>pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care</description>
          </group>
          <group group_id="O2">
            <title>Pemetrexed + Cisplatin Followed by Placebo</title>
            <description>pemetrexed + cisplatin followed by placebo plus best supportive care</description>
          </group>
        </group_list>
        <measure>
          <title>Independently-assessed Objective Progression-free Survival (PFS)</title>
          <description>To further evaluate the robustness of the PFS analysis, Lilly established an independent review of PFS to assess the potential for investigator bias in the determination of objective PD. PFS was measured from the date of randomization to the first date of objectively determined PD or death. For patients alive as of the data cutoff date and who did not have PD, PFS was censored at the date of the last objective tumor assessment. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD = 20% increase in sum of longest diameter of target lesions.</description>
          <population>Randomized participants with reviewable scan--(316/359 [88%] Maintenance arm and 156/180 [87%] Placebo comparator arm. The majority of unread scans (12.4%) were due to participants not completing 1 cycle of treatment by the data cutoff date (30 June 2010).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.94" lower_limit="2.96" upper_limit="4.24"/>
                    <measurement group_id="O2" value="2.60" lower_limit="2.23" upper_limit="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>0.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>OS is the duration from enrollment to death. For patients who are alive, OS is censored at the last contact.</description>
        <time_frame>Date of randomization to the date of death from any cause up to 39.5 months</time_frame>
        <population>All randomized participants. In the Pemetrexed maintenance arm 103 (28.7%) participants were censored and in the Placebo maintenance arm 39 (21.7%) participants were censored.</population>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed</title>
            <description>pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care</description>
          </group>
          <group group_id="O2">
            <title>Pemetrexed + Cisplatin Followed by Placebo</title>
            <description>pemetrexed and cisplatin followed by placebo plus best supportive care</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS is the duration from enrollment to death. For patients who are alive, OS is censored at the last contact.</description>
          <population>All randomized participants. In the Pemetrexed maintenance arm 103 (28.7%) participants were censored and in the Placebo maintenance arm 39 (21.7%) participants were censored.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.86" lower_limit="12.75" upper_limit="16.03"/>
                    <measurement group_id="O2" value="11.01" lower_limit="9.95" upper_limit="12.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Type 1 (alpha) error was controlled for the analyses of both PFS and OS in order to maintain an overall two-sided alpha level of 0.05 using a statistical gatekeeping and alpha spending scheme. The unconditional statistical power of the final OS analysis was 93%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0195</p_value>
            <p_value_desc>The predefined alpha for the final analysis of OS is 0.0498 for the unadjusted log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
            <estimate_desc>Unadjusted HR from Cox model with treatment as the only cofactor.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the EuroQol Instrument (EQ-5D) Index Score</title>
        <description>The EQ-5D is a generic instrument that describes health status in 5 attributes (mobility, self-care, pain/discomfort, anxiety/depression, usual activities) using a three level scale (no problem, some problems, and major problems). These combinations of attributes are converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score range from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension).</description>
        <time_frame>Baseline randomization through 30-day post-discontinuation visit (up to 19.3 months)</time_frame>
        <population>Participants who were randomized and completed the EQ-5D at baseline and at least once post-baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed</title>
            <description>pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care</description>
          </group>
          <group group_id="O2">
            <title>Pemetrexed + Cisplatin Followed by Placebo</title>
            <description>pemetrexed + cisplatin followed by placebo plus best supportive care</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the EuroQol Instrument (EQ-5D) Index Score</title>
          <description>The EQ-5D is a generic instrument that describes health status in 5 attributes (mobility, self-care, pain/discomfort, anxiety/depression, usual activities) using a three level scale (no problem, some problems, and major problems). These combinations of attributes are converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score range from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension).</description>
          <population>Participants who were randomized and completed the EQ-5D at baseline and at least once post-baseline.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.21"/>
                    <measurement group_id="O2" value="0.79" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 1 (n=265, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.15"/>
                    <measurement group_id="O2" value="-0.01" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1 (n=241, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.19"/>
                    <measurement group_id="O2" value="0.01" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1 (n=160, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.15"/>
                    <measurement group_id="O2" value="0.03" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1 (n=149, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.15"/>
                    <measurement group_id="O2" value="0.02" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 1 (n=108, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.16"/>
                    <measurement group_id="O2" value="0.01" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 1 (n=98, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.18"/>
                    <measurement group_id="O2" value="0.04" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 1 (n=73, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.20"/>
                    <measurement group_id="O2" value="0.01" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 1 (n=64, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.18"/>
                    <measurement group_id="O2" value="0.05" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 Day 1 (n=48, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.20"/>
                    <measurement group_id="O2" value="0.06" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 1 (n=39, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.16"/>
                    <measurement group_id="O2" value="0.08" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 1 (n=33, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.19"/>
                    <measurement group_id="O2" value="0.04" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 1 (n=28, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.27"/>
                    <measurement group_id="O2" value="0.06" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 1 (n=15, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.27"/>
                    <measurement group_id="O2" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 1 (n=11, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.26"/>
                    <measurement group_id="O2" value="0.03" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 1 (n=12, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.34"/>
                    <measurement group_id="O2" value="0.01" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 1 (n=7, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.36"/>
                    <measurement group_id="O2" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 1 (n=3, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="0.43"/>
                    <measurement group_id="O2" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 1 (n=2, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.52"/>
                    <measurement group_id="O2" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day Post-Study Visit (n=82, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.27"/>
                    <measurement group_id="O2" value="-0.09" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EuroQol Instrument (EQ-5D) Visual Analog Scale (VAS)</title>
        <description>Patients indicate their present health state through completion of the VAS. Possible scores range from 0 (worst imaginable health state) to 100 (best imaginable health state).</description>
        <time_frame>Baseline randomization through 30-day post-discontinuation visit (up to 19.3 months)</time_frame>
        <population>Participants who were randomized and completed the EQ-5D at baseline and at least once post-baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed</title>
            <description>pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care</description>
          </group>
          <group group_id="O2">
            <title>Pemetrexed + Cisplatin Followed by Placebo</title>
            <description>pemetrexed + cisplatin followed by placebo plus best supportive care</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EuroQol Instrument (EQ-5D) Visual Analog Scale (VAS)</title>
          <description>Patients indicate their present health state through completion of the VAS. Possible scores range from 0 (worst imaginable health state) to 100 (best imaginable health state).</description>
          <population>Participants who were randomized and completed the EQ-5D at baseline and at least once post-baseline.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.1" spread="16.6"/>
                    <measurement group_id="O2" value="71.0" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 1 (n=266, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" spread="9.86"/>
                    <measurement group_id="O2" value="1.42" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1 (n=239, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" spread="11.2"/>
                    <measurement group_id="O2" value="3.15" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1 (n=162, 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" spread="10.9"/>
                    <measurement group_id="O2" value="4.90" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1 (n=147, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" spread="13.1"/>
                    <measurement group_id="O2" value="6.15" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 1 (n=107, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.55" spread="12.4"/>
                    <measurement group_id="O2" value="5.99" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 1 (n=98, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.01" spread="12.5"/>
                    <measurement group_id="O2" value="5.76" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 1 (n=74, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="14.5"/>
                    <measurement group_id="O2" value="3.98" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 1 (n=64, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.12" spread="14.1"/>
                    <measurement group_id="O2" value="7.58" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 Day 1 (n=47, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.19" spread="14.2"/>
                    <measurement group_id="O2" value="7.61" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 1 (n=37, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.14" spread="15.1"/>
                    <measurement group_id="O2" value="6.23" spread="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 1 (n=33, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.58" spread="14.7"/>
                    <measurement group_id="O2" value="0.94" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 1 (n=27, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="16.0"/>
                    <measurement group_id="O2" value="4.63" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 1 (n=14, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.29" spread="16.4"/>
                    <measurement group_id="O2" value="10.0" spread="3.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 1 (n=11, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.64" spread="18.4"/>
                    <measurement group_id="O2" value="14.0" spread="4.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 1 (n=10, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.40" spread="12.9"/>
                    <measurement group_id="O2" value="12.0" spread="3.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 1 (n=6, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.83" spread="9.99"/>
                    <measurement group_id="O2" value="15.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 1 (n=3, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="21.1"/>
                    <measurement group_id="O2" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 1 (n=2, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="14.1"/>
                    <measurement group_id="O2" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 days post-study (n=78, 49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.77" spread="17.3"/>
                    <measurement group_id="O2" value="-3.92" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Hospitalizations Due to Adverse Events or Requiring Transfusion (Resource Utilization)</title>
        <time_frame>Baseline randomization through 30-day post-discontinuation visit (up to 19.3 months)</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed</title>
            <description>pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care</description>
          </group>
          <group group_id="O2">
            <title>Pemetrexed + Cisplatin Followed by Placebo</title>
            <description>pemetrexed + cisplatin followed by placebo plus best supportive care</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hospitalizations Due to Adverse Events or Requiring Transfusion (Resource Utilization)</title>
          <population>All randomized participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hospitalization due to Drug-related Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4"/>
                    <measurement group_id="O2" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transfusions Packed Red Blood Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3"/>
                    <measurement group_id="O2" value="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transfusions Whole Blood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transfusions Platelets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transfusions Fresh Frozen Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Non-Serious Adverse Event (AE) During Maintenance Phase</title>
        <description>A summary of non-serious AEs is located in the Reported Adverse Event Module.</description>
        <time_frame>Baseline randomization through 30-day post-discontinuation visit (up to 49.7 months)</time_frame>
        <population>Randomized population with 2% cut-off threshold for inclusion for 19.3 months and 5% for 49.7 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed</title>
            <description>pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care</description>
          </group>
          <group group_id="O2">
            <title>Pemetrexed Plus Cisplatin Followed by Placebo</title>
            <description>pemetrexed + cisplatin followed by placebo plus best supportive care</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Non-Serious Adverse Event (AE) During Maintenance Phase</title>
          <description>A summary of non-serious AEs is located in the Reported Adverse Event Module.</description>
          <population>Randomized population with 2% cut-off threshold for inclusion for 19.3 months and 5% for 49.7 months.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-Serious AEs at 2% Threshold: up to 19.3 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.9"/>
                    <measurement group_id="O2" value="50.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Serious AEs at 5% Threshold: up to 49.7 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5"/>
                    <measurement group_id="O2" value="62.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Serious Adverse Events During Maintenance Phase</title>
        <description>A summary of serious adverse events is located in the Reported Adverse Event Module.</description>
        <time_frame>Baseline randomization through 30-day post-discontinuation visit (up to 49.7 months)</time_frame>
        <population>Randomized population with all serious adverse events included.</population>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed</title>
            <description>pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care</description>
          </group>
          <group group_id="O2">
            <title>Pemetrexed Plus Cisplatin Followed by Placebo</title>
            <description>pemetrexed + cisplatin followed by placebo plus best supportive care</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serious Adverse Events During Maintenance Phase</title>
          <description>A summary of serious adverse events is located in the Reported Adverse Event Module.</description>
          <population>Randomized population with all serious adverse events included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events: up to 19.3 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9"/>
                    <measurement group_id="O2" value="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events: up to 49.7 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2"/>
                    <measurement group_id="O2" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Objective Tumor Response (Response Rate) During Maintenance Phase of Study up to Primary Data Cut-Off</title>
        <description>Analysis for combined phases was not performed since response was calculated separately for each phase of study. Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response(PR)is at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease(PD) is at least a 20% increase in sum of longest diameter of target lesions; Stable Disease(SD)=no change or small changes that do not meet the above criteria for CR, PR, or PD.</description>
        <time_frame>Baseline to date of measured progressive disease (up to 19.3 months)</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed</title>
            <description>pemetrexed and cisplatin followed by maintenance pemetrexed and best supportive care</description>
          </group>
          <group group_id="O2">
            <title>Pemetrexed + Cisplatin Followed by Placebo</title>
            <description>pemetrexed + cisplatin followed by placebo plus best supportive care</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Objective Tumor Response (Response Rate) During Maintenance Phase of Study up to Primary Data Cut-Off</title>
          <description>Analysis for combined phases was not performed since response was calculated separately for each phase of study. Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response(PR)is at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease(PD) is at least a 20% increase in sum of longest diameter of target lesions; Stable Disease(SD)=no change or small changes that do not meet the above criteria for CR, PR, or PD.</description>
          <population>All randomized participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2"/>
                    <measurement group_id="O2" value="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Independently-Assessed Objective Tumor Response (Response Rate) During Maintenance Phase Up to Primary Data Cut-Off</title>
        <description>Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response (PR) is at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) is at least a 20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=no change or small changes that do not meet the above criteria for CR, PR, or PD. Response Rate = (CR+PR)/Participants in Arm*100. Disease Control Rate=(CR+PR+SD)/Number of Participants in Arm*100.</description>
        <time_frame>Date of randomization to date of measured PD (up to 19.3 months)</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed</title>
            <description>pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care</description>
          </group>
          <group group_id="O2">
            <title>Pemetrexed + Cisplatin Followed by Placebo</title>
            <description>pemetrexed + cisplatin followed by placebo plus best supportive care</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Independently-Assessed Objective Tumor Response (Response Rate) During Maintenance Phase Up to Primary Data Cut-Off</title>
          <description>Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response (PR) is at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) is at least a 20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=no change or small changes that do not meet the above criteria for CR, PR, or PD. Response Rate = (CR+PR)/Participants in Arm*100. Disease Control Rate=(CR+PR+SD)/Number of Participants in Arm*100.</description>
          <population>All randomized participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Response Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2" lower_limit="41.0" upper_limit="51.6"/>
                    <measurement group_id="O2" value="42.2" lower_limit="34.9" upper_limit="49.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Control Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1" lower_limit="96.0" upper_limit="99.2"/>
                    <measurement group_id="O2" value="94.4" lower_limit="90.0" upper_limit="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose of maintenance therapy up to 44 Cycles (Cycle=21 days) plus 30 days post-therapy discontinuation</time_frame>
      <desc>Adverse events were updated to add the adverse events for participants who were still on study therapy at the time of the last patient visit for the primary outcome measure to those events previously reported from first dose of maintenance therapy up to 19.3 months.</desc>
      <group_list>
        <group group_id="E1">
          <title>Induction Pemetrexed + Cisplatin</title>
          <description>pemetrexed: 500 mg/m^2, intravenous (IV), on Day 1 of each 21-day cycle for 4 cycles.
cisplatin: 75 mg/m^2, IV, on Day 1 of each 21-day cycle for 4 cycles.</description>
        </group>
        <group group_id="E2">
          <title>Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed</title>
          <description>pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care</description>
        </group>
        <group group_id="E3">
          <title>Pemetrexed + Cisplatin Followed by Placebo</title>
          <description>pemetrexed and cisplatin followed by placebo plus best supportive care</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="251" subjects_at_risk="939"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="939"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Febrile bone marrow aplasia</sub_title>
                <description>1 event in the Induction arm resulted in death</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="939"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="939"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="939"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="939"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <description>1 event in the Induction arm and the event in the Pemetrexed + Cisplatin followed by placebo arm resulted in death.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <description>These events resulted in death.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="939"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <description>1 event in the Induction arm resulted in death.</description>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="939"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <description>This event resulted in death.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <description>1 event in the Induction arm resulted in death.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="27" subjects_affected="23" subjects_at_risk="939"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Neutropenic colitis</sub_title>
                <description>The event in the Induction arm resulted in death.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="34" subjects_affected="29" subjects_at_risk="939"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="939"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="939"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="939"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <description>This event resulted in death.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="939"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="359"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="939"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <description>1 event in the Induction arm resulted in death.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Lung infection pseudomonal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>1 event in the Induction arm and 1 event in the Pemetrexed + Cisplatin followed by Maintenance Pemetrexed arm resulted in death.</description>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="939"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="359"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Rotavirus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <description>1 event in the Induction arm resulted in death.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Fracture displacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Tracheal obstruction</sub_title>
                <description>This event resulted in death.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Venous injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Biopsy pleura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Blood creatinine decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hypercreatininaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Spinal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Spondylitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Tumour necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <description>2 events in the Induction arm resulted in death.</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="939"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pyramidal tract syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder diverticulum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <description>1 event in the Induction arm resulted in death.</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="939"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <description>2 events in the Induction arm resulted in death.</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <description>This event resulted in death.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <description>This event resulted in death.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <description>1 event in the Induction arm resulted in death.</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="939"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="359"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="939"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <description>3 events in the Induction arm resulted in death.</description>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="939"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="359"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <description>1 event in the Induction arm resulted in death.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <description>This event resulted in death.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <description>The two events in the Induction arm resulted in death.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Catheter removal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Ischaemic limb pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Jugular vein distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Superior vena cava syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="939"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="939"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="750" subjects_at_risk="939"/>
                <counts group_id="E2" subjects_affected="271" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="112" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="156" subjects_affected="141" subjects_at_risk="939"/>
                <counts group_id="E2" events="72" subjects_affected="58" subjects_at_risk="359"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="233" subjects_affected="154" subjects_at_risk="939"/>
                <counts group_id="E2" events="47" subjects_affected="25" subjects_at_risk="359"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="157" subjects_affected="126" subjects_at_risk="939"/>
                <counts group_id="E2" events="23" subjects_affected="19" subjects_at_risk="359"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="124" subjects_affected="110" subjects_at_risk="939"/>
                <counts group_id="E2" events="27" subjects_affected="22" subjects_at_risk="359"/>
                <counts group_id="E3" events="12" subjects_affected="6" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="537" subjects_affected="358" subjects_at_risk="939"/>
                <counts group_id="E2" events="45" subjects_affected="36" subjects_at_risk="359"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="281" subjects_affected="207" subjects_at_risk="939"/>
                <counts group_id="E2" events="30" subjects_affected="24" subjects_at_risk="359"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="171" subjects_affected="138" subjects_at_risk="939"/>
                <counts group_id="E2" events="49" subjects_affected="41" subjects_at_risk="359"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="203" subjects_affected="176" subjects_at_risk="939"/>
                <counts group_id="E2" events="49" subjects_affected="35" subjects_at_risk="359"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="54" subjects_affected="50" subjects_at_risk="939"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="359"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="53" subjects_affected="41" subjects_at_risk="939"/>
                <counts group_id="E2" events="47" subjects_affected="41" subjects_at_risk="359"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="49" subjects_affected="45" subjects_at_risk="939"/>
                <counts group_id="E2" events="45" subjects_affected="34" subjects_at_risk="359"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="133" subjects_affected="116" subjects_at_risk="939"/>
                <counts group_id="E2" events="34" subjects_affected="28" subjects_at_risk="359"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="31" subjects_affected="29" subjects_at_risk="939"/>
                <counts group_id="E2" events="23" subjects_affected="18" subjects_at_risk="359"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="939"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="359"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="67" subjects_affected="64" subjects_at_risk="939"/>
                <counts group_id="E2" events="28" subjects_affected="24" subjects_at_risk="359"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="76" subjects_affected="70" subjects_at_risk="939"/>
                <counts group_id="E2" events="43" subjects_affected="37" subjects_at_risk="359"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="48" subjects_affected="47" subjects_at_risk="939"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="359"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

